Search by PDG name  
   

 

ITGAV  
    


    
      Official symbol:  ITGAV
      Full name:  integrin subunit alpha V
      Location:  2q32.1
      Also known as:  VTNR, MSK8, VNRA, CD51
      Entrez ID:  3685
      Ensembl ID:  ENSG00000138448
      Summary:  The product of this gene belongs to the integrin alpha chain family. Integrins are heterodimeric integral membrane proteins composed of an alpha subunit and a beta subunit that function in cell surface adhesion and signaling. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha V subunit. This subunit associates with beta 1, beta 3, beta 5, beta 6 and beta 8 subunits. The heterodimer consisting of alpha V and beta 3 subunits is also known as the vitronectin receptor. This integrin may regulate angiogenesis and cancer progression. Alternative splicing results in multiple transcript variants. Note that the integrin alpha 5 and integrin alpha V subunits are encoded by distinct genes. [provided by RefSeq, Oct 2015]

    

    
  Overall distribution
    
  Tissue specific distribution
    
 
  
 
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Gscore (Amp):  0.12  
Gscore (Del):  0.16  
 
Recurrently amplified in 1 cancer type(s)
Recurrently deleted in 1 cancer type(s)
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Mscore:  0.00  
 
   

    
  Overall
    
  Tissue specific
    
 
Total fusion occurrence:  5  
 
Fusions detected in 5 cancer type(s)
 
 

    
  Overall
    
  Tissue specific
    
   RNAi: STRONGLY SELECTIVE 
   
   

    
      Functional class:  Not specified
      JensenLab PubMed score:  407.19  (Percentile rank: 89.23%)
      PubTator score:  468.15  (Percentile rank: 92.92%)
      Target development/druggability level:  TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below.
      Tractability (small molecule):  Discovery PrecedenceTargets with ligands; Targets with crystal structures with ligands
      Tractability (antibody):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets

    







Contact us | | Terms & Conditions.
Copyright © 2020 University of Pennsylvania. All Rights Reserved.